Please login to the form below

Not currently logged in
Email:
Password:

Pfizer post-marketing site

US pharma company pledges commitment to post-marketing with launch of new website

missing image filePfizer, has launched a website to provide up-to-date, user-friendly information on the status of its US post-marketing commitments (PMCs).

The initiative is the first of its kind for a pharmaceutical company.

PMCs are studies conducted after a medicine receives regulatory approval, generally as a requirement for approval or continued marketing of some drugs. The studies are designed to provide additional information about a treatment's safety, efficacy or optimal use.

The website provides study descriptions and status of Food and Drug Administration (FDA) post-marketing commitments, current due dates, a complete list of Pfizer PMCs, and general information about the PMC process.

The FDA first posted a database of the pharmaceutical industry's post-marketing commitments on its public-facing website in 2003. Pfizer's new site expands the information available, presented with user-friendly search functions, a glossary of terms, and frequently asked questions about PMCs.

Users can access Pfizer's regulatory commitments for prescription products using the treatment name, approval date and study status.

"From a medical compound's discovery, through its development, and for as long as it is prescribed, each of our medicines undergoes thorough safety and efficacy monitoring and evaluation in collaboration with health authorities around the world," said Pfizer's chief medical officer, Joseph Feczko.

ìThis kind of transparency helps encourage patients to ask their physicians about treatment options. When these conversations happen, they often help patients better understand the risks and benefits of different treatment options.î

The site will be updated weekly by Pfizer and can be accessed using the following link: www.pfizer.com/pmc.

 

19th June 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics